NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review

NovoCure Ltd

2025-Q3 EPS reported -$1.00 revenue$481,003,000

Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.
Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.
4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.
PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.
Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.